Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 1, 2001, Pages 113-116

  Torti, Carlo ^a   Pozniak, Anton ^a   Nelson, Mark ^a   Hertogs, Kurt ^b   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; VIRUS GENE; VIRUS MUTATION;

EID: 0034928482     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.1.113     Document Type: Article

References (7)

1. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
2. The Atlantic study: A randomized, open label trial comparing two protease inhibitors (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
3. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS Society-USA panel
4. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
5. The presence or absence of zidovudine in a nevirapine-containing antiretroviral regimen determines which of two nevirapine-limiting mutations occurs on virologic failure
6. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine and nevirapine
7. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen